Project Grant 7200AA22FA00040

This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the federal Child Health and Human Development Extramural Research program (CFDA 93.865), provides $220,000.00 to Seattle Children's Hospital to develop and evaluate the "Presumptively Initiating Vaccines and Optimizing Talk for Inpatients (PIVOT-IN)" intervention. The goal of this project is to improve routine vaccination of vaccine-eligible children during their hospital stays....

This $161,616 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to understand the development of mucosal immunity to poliovirus. The research aims to characterize human immune responses during oral poliovirus (OPV) vaccination, investigate the impact of vaccine priming and gut microbiota on mucosal immunity, and evaluate the potential of a novel mucosal adjuvant...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $1,162,224 to the University of Pittsburgh to optimize and evaluate an oral Bacille Calmette-Guérin (BCG) vaccine regimen against tuberculosis (TB). The key objectives are to: 1) optimize an oral BCG vaccination approach, 2) compare the efficacy of oral BCG to the current standard intradermal and intravenous BCG...

The Fogarty International Center, under the International Research and Research Training program (CFDA 93.989), awarded a $186,254 Project Grant to the Ifakara Health Institute in Tanzania. The grant supports an implementation trial to investigate the potential of synchronized dog vaccination campaigns to improve coverage and cost-effectiveness compared to traditional team-led delivery approaches in East Africa. The research aims to: 1) determine if synchronized vaccination campaigns can...

This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) provides $1,771,342 to North Carolina State University to develop a novel method of oral cavity mucosal vaccination. The research aims to establish a new paradigm in oral mucosal vaccination by using dental floss to target the junctional epithelium, a highly permeable tissue at the base of the gum pocket, for vaccine...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $690,500 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Trustees of Boston University's Medical Campus to investigate the limited effectiveness of the booster dose of the RTS,S malaria vaccine in African children. The project aims to comprehensively analyze the immune mechanisms underlying the poor antibody responses to the booster dose, including the impacts of repeated malaria...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $645,378 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Emory University to develop a self-administered microneedle patch for the long-acting release of antiretroviral agents. The key objectives are to: 1) Formulate and optimize a microneedle patch for delivering the antiretroviral drug islatravir (efda) with at least one month of sustained release, and 2) Evaluate the in vivo...

This $375,000 federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) aims to evaluate the impact of a status-neutral, person-centric intervention called the "Blue Shed" on HIV transmission and outcomes among people who inject drugs (PWID) in New Delhi, India. The project has three key objectives: Assess the direct impact of the Blue Shed intervention on HIV incidence, viral suppression, and mortality among PWID...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,170,041 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Hawaii (UH) to study the long-term safety and effectiveness of the Dengvaxia dengue vaccine in the Philippines. The key objectives are to determine the baseline dengue virus serostatus of Dengvaxia recipients, assess the long-term safety and effectiveness of the vaccine, and characterize the antibody and...

This federal Project Grant award for $807,257, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to advance the development of a microneedle patch technology for delivering a cocktail of broadly neutralizing antibodies (bnAbs) to prevent HIV-1 transmission in breastfeeding infants. The project, led by Old Dominion University (ODU) and its affiliated research foundation (Odurf), will involve...